EXTON, Pa.--(BUSINESS WIRE)--Frontage today announced expansion plans for its clinical research operations and appointed new leadership to spearhead these efforts.
As a first step, Eileen McAuley, RN, MPA was named Senior Vice President, Clinical Services. She brings more than 25 years of clinical operations experience to Frontage, from project management coordination of functional research components to strategic leadership.
Most recently, Ms. McAuley served as Chief Operating Officer of Integrium, a therapeutically-focused, full-service contract research organization, with operations that span Phase I-IV.
Prior to Integrium, she was Senior Director, Clinical Operations for Alteon, a biotechnology organization focused on development of novel treatments for cardiovascular diseases.
“We are delighted to welcome Eileen McAuley to our senior leadership team at Frontage. She has exceptional skills in developing sustainable organizational growth, and can offer our clients guidance to effectively manage clinical research programs across multiple therapeutic areas,” said Carlos Orantes, Chief Operating Officer of Frontage Labs. “Ms. McAuley’s leadership abilities and experience will enable Frontage to enhance our service offerings and the overall value we deliver to our clients as we keep pace with the growing complexity of clinical development.”
As part of Frontage’s strategic growth plans to broaden clinical service capabilities and increase capacity, the company recently finalized plans to build a new 33,000 square foot clinical research center in Secaucus, NJ. This facility, scheduled to open during the final months of 2014, will complement the company’s existing clinical research center in nearby Hackensack, NJ. Planned enhancements include the ability to conduct a wider range of clinical studies, as well as multiple, concurrent studies and studies involving patient populations. The expansion will nearly triple the company’s clinical capacity in the US.
“By expanding our investment and infrastructure in clinical services, Frontage will be well-positioned to comprehensively support the early development needs of our clients,” said Song Li, CEO of Frontage.
Frontage’s clinical research services include the design and conduct of studies in healthy volunteers and various patient populations, supported by a comprehensive team of research professionals and a clinical center designed for efficient study conduct. Biometric services, including biostatistics, data management and medical writing, provide the supportive, turn-key capabilities to take clinical programs from start to finish.
Frontage helps biopharmaceutical organizations advance their research and development efforts with full service offerings– including bioanalysis, preclinical and clinical studies, analytical testing and product development support– spanning discovery stages through late-stage clinical trials. The company also provides turnkey product development, bioequivalence and analytical services to generic and consumer health pharmaceutical companies to support Abbreviated NDA and 505.b.2 application submissions.
With a 12-year history of bioanalytical, clinical research and CMC operations, eight state-of-the art research facilities and more than 300 professionals in the US and China, Frontage has enabled biopharmaceutical and generic companies of all sizes to advance hundreds of molecules through clinical development and commercial launch in global markets. For more information, visit www.frontagelab.com.
